Announcement on the 2018 Profit Distribution Plan
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2019-015
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2018 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
l
Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") 2018 Profit Distribution Plan is based on 2018 year-end share capital ,344,083, 828 shares, cash dividends 3.0 yuan (tax included) are distributed for every 10 shares, and the total cash dividends to all shareholders registered on the equity registration date are 103,225,148.40 yuan (tax included).
l
Review Procedure: This profit distribution plan has been reviewed and approved at the 10th meeting of the 10th Board of Directors of the Company, and still needs to be submitted to the 2018 Annual General Meeting of Shareholders of the Company for review.
1. 2018 The main contents of the profit distribution plan
are audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of 2018 is ,588,502,101.59 yuan. Net profit in accounting statement of parent company ,433,675,496.73 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 43,367,549.67 yuan, plus undistributed profit 658,978,622.43 yuan at the beginning of the year, minus 2017 annual cash dividend 34,408,382.80 yuan, and the distributable profit for this year is 1,014,878,186.69 yuan.
Company plans to make cash distribution in 2018 . Based on 2018 year-end share capital ,344,083, 828 shares, it will distribute cash dividends 3.0 yuan (including tax) per 10 shares, and the total amount of cash dividends to all shareholders registered on the equity registration date will be , 225,148.40 yuan (tax included).
2018 year will not carry out provident fund to increase share capital.
2. Profit Distribution Plan Description
( 1 ) Implementation of the Company's Cash Dividend Policy
The Articles of Association of the Company stipulate that the accumulated profits distributed in cash in the last three years shall not be less than the 30% of the average annual distributable profits realized in the last three years.
The proportion of the company's accumulated profits distributed in cash in the last three years to the average annual distributable profits realized in the last three years is 89.59 , which is in line with the cash dividend policy stipulated in the company's "Articles of Association.
( 2 ) Company's Development
At present, the company is in the stage of accelerated development. The company will speed up the project of Guizhou Huangpinggu Longmingchuan Cement Co., Ltd. On the basis of acquiring the 100% equity of the company, the company will continue to invest about 6.5 .3 billion yuan to build a new dry cement production line with a daily output of of 4500 tons of cement clinker (with waste heat for power generation); the total investment for the project of producing 20 .7 billion solid preparations in Jinxi production base of Jianfeng pharmaceutical industry with an annual output of is expected to be 50146 .49 million yuan, and 2019 will carry out plant construction and equipment procurement. Anhui Zhongwang, a subsidiary of Shanghai Beika, a subsidiary of Jianfeng Pharmaceutical Company, will carry out the second phase of technological transformation to build an intermediate and bulk drug base for the company's pharmaceutical sector. In addition, spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor new drug "DPT " has entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. The development of the above-mentioned business requires large financial support.
( 3 ) Considering that the company has invested a lot in technological transformation and new product development in 2018 , in order to maintain the company's stable operation and support the company's long-term development, Taking into account the short-term and long-term interests of shareholders, the board of directors approved the above-mentioned 2018 profit distribution plan.
( 4 ) The company will hold a 2018 annual performance and cash dividend explanation meeting to communicate and exchange with investors on the company's 2018 annual performance and cash dividend matters, and timely answer investors' concerns.
3. Review Procedure
2019 4 26 , the company held the 184 meeting of the 10th 183 of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on his behalf, comply with the relevant provisions of the "Company Law" and the "Articles of Association" of the company, and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the company's 2018 profit distribution plan was deliberated and approved with 9 votes in favor, 0 votes against, and 0 abstentions.
2018 Annual General Meeting of Shareholders for deliberation. When the company convenes the general meeting of shareholders, it will provide investors with online voting facilities.
2018 :
, and the independent director agreed that the company should use 2018 year-end share capital ,344,083, 828 as the base, A cash dividend of 3.0 yuan (tax included) will be distributed to 10 shares of , and the total amount of cash dividends distributed to all shareholders registered on the date of equity registration is ,148.40 yuan (tax included), No provident fund will be converted into share capital in 2018 .
. The profit distribution plan is formulated according to the actual operating results and financial situation of the company 2018 , and in combination with the actual needs of the company's future business development. The retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company and the long-term interests of shareholders, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors believe that the plan complies with the relevant provisions of the Company's Articles of Association on profit distribution and the actual operating conditions of the Company.
3 , the company's board of directors considered and approved the above profit distribution plan. The independent directors believe that the convening, convening, and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the "Articles of Association", and are legal and effective; and agree to submit the plan to the company's 2018 Annual General Meeting for deliberation.
5. Related Risk Tips
This profit distribution plan must be submitted to the company's 2018 annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April 30, 2019
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05